calpain has been researched along with Coronary-Disease* in 5 studies
1 review(s) available for calpain and Coronary-Disease
Article | Year |
---|---|
Contribution of calcium-activated neutral protease to the degradation process of ischemic heart.
Topics: Animals; Calpain; Coronary Disease; Dogs; Humans; Muscle Proteins; Myocardium; Piperazines; Platelet Aggregation; Protease Inhibitors; Rabbits | 1991 |
4 other study(ies) available for calpain and Coronary-Disease
Article | Year |
---|---|
Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American Coronary Artery Disease Study.
The powerful relation between atherosclerosis and diabetes may have a common genetic basis. However, few genes predisposing to both have been identified. Calpain-10 (CAPN10) was the first gene for type 2 diabetes identified by positional cloning, wherein a combination of haplotypes conferred increased risk of diabetes. We sought to determine whether CAPN10 influences subclinical atherosclerosis. Among nondiabetic subjects from 85 Mexican-American families with a history of coronary artery disease, subclinical atherosclerosis was assessed by common carotid artery intima-media thickness (IMT), insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp, and insulin secretion was estimated by the oral glucose tolerance test. These phenotypes were tested for association with CAPN10 haplotypes. Haplotype 1112 (of single nucleotide polymorphisms [SNPs] 44, 43, 56, and 63) was associated with increased IMT, while haplotype 1221 was associated with decreased IMT. The 112/121 haplotype combination (of SNPs 43, 56, and 63), originally found to confer increased risk for diabetes, was associated with the largest IMT in our study population. CAPN10 was also associated with both insulin sensitivity and insulin secretion. Covariate analysis suggested that CAPN10 affects IMT independently of these diabetes-related phenotypes. The fact that the diabetes gene CAPN10 also influences the risk for atherosclerosis shows that inherited factors may underlie the frequent co-occurrence of these two conditions. Topics: Adolescent; Adult; Aged; Arteriosclerosis; Calpain; Carotid Artery Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Insulin Resistance; Male; Mexican Americans; Middle Aged; Phenotype; Tunica Intima | 2005 |
Calpain activity alters in rat myocardial subfractions after ischemia or reperfusion.
To examine whether calpain is activated during ischemic or reperfusion injury, we measured calpain activity of the subfractions of rat myocardia after global ischemia for 60 min or the ischemia followed by 30 min reperfusion by the Langendorff procedure. The myocardial homogenate was fractionated into 600 x g, 10,000 x g and 100,000 x g pellet fractions as well as 10,000 x g supernatant fraction. The supernatant fraction was further subjected to DEAE cellulose and phenyl-Sepharose chromatographies to separate mu- and m-calpains. The m-calpain activity of the DEAE fractions after global ischemia for 60 min was higher but that after ischemia-reperfusion was lower than that of the control. On the other hand, the ischemia-reperfusion but not ischemia by itself raised the calpain activity of the phenyl-Sepharose fraction (mu-calpain) and the 10,000 x g pellet measured at 100 microM and 5 mM Ca2+. Treatment with verapamil but not with ryanodine during ischemia attenuated the increase in m-calpain activity. A dot-blotting analysis of calpain antigenicity showed a decrease in soluble but no change in the particulate fractions after ischemia-reperfusion. An immunoblotting technique did not detect proteolysis of the calpain 80-kDa subunit. These observations suggest that calpain is activated by Ca2+ influx during ischemia and reperfusion without gross changes in its amount. Some unknown processes other than translocation or autolysis are thought to be involved in the alterations. Topics: Animals; Calpain; Coronary Disease; Male; Myocardial Reperfusion; Myocardium; Proteins; Rats; Rats, Wistar; Ryanodine; Subcellular Fractions; Verapamil | 1993 |
[Clinical significance of kininogen-proteinase complex analysis in biochemical laboratory tests].
Topics: Calpain; Cathepsins; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Humans; Kininogens; Specimen Handling | 1989 |
Degradation of myocardial structural proteins in myocardial infarcted dogs is reduced by Ep459, a cysteine proteinase inhibitor.
The purpose of this study is to clarify whether cysteine proteinases play an important role in the degradation of myocardial proteins in the infarcted tissue. We studied the effects of a cysteine proteinase inhibitor, Ep459, on degradation of cardiac structural proteins caused by ischemia due to coronary artery ligation for 24 h. Proteolytic effects of purified cysteine proteinases on isolated cardiac tissue were also examined. Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, degradation of cardiac structural proteins, particularly of myosin heavy chain, alpha-actinin and troponin-I was observed in the infarcted tissue. Treatment with Ep459 significantly reduced protein degradation and total activity of cathepsins B and L in the infarcted tissue, compared with the findings in the untreated group. The electrophoretic pattern of the infarcted myocardium was similar to that of myofibrillar proteins degraded by cathepsins B and L. These results suggest that cysteine proteinases, particularly cathepsins B and L, are involved in degradation of myofibrillar proteins in myocardial infarction. Topics: Animals; Calpain; Cathepsin B; Cathepsin L; Cathepsins; Coronary Disease; Cysteine Endopeptidases; Dogs; Electrophoresis, Polyacrylamide Gel; Endopeptidases; Female; Kinetics; Leucine; Male; Muscle Proteins; Myocardial Infarction; Myocardium; Protease Inhibitors | 1986 |